Evidence map›Paper›PMID 36879567›Full record

ArticleArchives of rheumatology2022

MiRNA-23a-5p is the biomarkers for gouty arthritis and promotes inflammation in rats of gouty arthritis via MyD88/NF-κB pathway by induction TLR2.

Fang Li, Jian-Hua Yao, Li Li, Qian Nie, Jing-Jing Cao, Xiao-Ran Ning

Open access · diamondAbstract read
In one paragraph

Article in Archives of rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fang LiDepartment of Rheumatism and Immunology, Hebei General Hospital, Shijiazhuang, China.ORCID 0000-0002-8673-5600
Jian-Hua YaoDepartment of Geratology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.ORCID 0000-0002-4760-0332
Li LiDepartment Ultrasonograph, Hebei General Hospital, Shijiazhuang, China.ORCID 0000-0003-3646-8484
Qian NieHebei General Hospital, Medicai Examination Center, Shijiazhuang, China.ORCID 0000-0001-5394-2382
Jing-Jing CaoDepartment of Rheumatism and Immunology, Hebei General Hospital, Shijiazhuang, China.ORCID 0000-0003-2145-7715
Xiao-Ran NingDepartment of Rheumatism and Immunology, Hebei General Hospital, Shijiazhuang, China.ORCID 0000-0003-3526-5677
Hebei General Hospital · CNSecond Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: In this study, we aimed to examine the efficacy of micro ribonucleic acid (miRNA)-23a-5p in gouty arthritis and to investigate its possible mechanism. Materials and methods: Gouty arthritis in rat was established by intraarticular injection of 0.2 mL monosodium urate crystal (20 mg/mL) inside knee joint cavity. THP-1 cell was induced using lipopolysaccharides (LPS) for Results: Serum miRNA-23a-5p expression levels were increased in rats of gouty arthritis. However, overexpression of miRNA-23a-5p promoted inflammation and induced myeloid differential protein-88 (MyD88)/nuclear factor-kappa B (NF-κB) pathway by induction toll-like receptor-2 (TLR2) Conclusion: Our findings demonstrate that miRNA-23a-5p is a biomarker for gouty arthritis and promotes inflammation in rats of gouty arthritis via MyD88/NF-κB pathway by targeting TLR2.

Indexed as

Gouty arthritisinflammationmiRNA-23a-5pMyD88NF-κBTLR2.

Identifiers

PMID36879567
PMCPMC9985376
OpenAlexW4312578647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.